Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

At the moment, the company is developing novel therapeutic approaches for patients with underserved heart issues, such as ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

The WATCHMAN FLX device showed superior safety with 8.5% major bleeding ... following a cardiac ablation were presented at ...